March 9th, 2007 Curalogic has started clinical EU phase III trial with its ragweed product Resume: Curalogic has dosed the first patients in the clinical EU phase III trial (RPE 04) with the product for treatment of ragweed allergy. The trial is planned to include 550 patients in USA and Europe. Curalogic has dosed the first patients in the clinical EU phase III trial (RPE 04) with the product for oral treatment of ragweed allergy.
